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Vitamin D Metabolism in Health and Disease 
Norman H. Bell, MD' 
1,25-Dihydroxyvitamin D3 Receptor Structure 
and Function 
In this portion ofthe program the most recent information con-ceming factors that regulate the production and biologic ac-
tion of 1,25-dihydroxyvitamin D, the most active metabolite of 
vitamin D, in normal and disease states was presented. Haussler 
(1) described the stmcture and functional domains of the recep-
tor for 1,25-dihydroxyvitamin D. The human receptor is a poly-
peptide containing 427 amino acids with an N-terminal DNA 
binding domain (150 amino acids) and a C-terminal hormone 
binding domain (226 amino acids) that are separated by a 
"hinge" (51 amino acids). The DNA binding region contains 
two "zinc fingers" that are thought to be important in binding of 
the 1,25-dihydroxyvitamin D-receptor complex to DNA (see 
below). The vitamin D receptor bears a striking resemblance to 
other nonpolypeptide hormonal receptors including the 
glucocorticoid receptor, estrogen receptor, retinoic acid recep-
tor, and thyroid receptor (1). Not surprising is the finding that 
there is a high degree of homology among the receptors at the 
DNA binding site. Haussler indicated that 1,25-dihydroxy-
vitamin D3 upregulates its receptor, that phosphorylation may 
occur in this process, and that upregulation may be phys-
iologically important by amplifying gene regulation and bio-
logic action. Although the mechanisms by which 1,25-di-
hydroxyvitamin D regulates gene expression are not known, 
Haussler proposed a model in which phosphorylation of the vi-
tamin D receptor is catalyzed by casein kinase and the hormone-
receptor-DNA complex initiates transcription (1). 
Hereditary Resistance to 1,25-Dihydroxyvitamin 
D: Pathophysiology, Diagnosis, and IVeatment 
Liberman and Marx (2) indicated that five defects in heredi-
tary vitamin D-dependent rickets, type I I , have been described 
based on studies of cellular uptake and nuclear binding of 
^H-1,25-dihydroxyvitamin D,. These are outiined as follows: 
Type I ; no binding of hormone to soluble cell extract or 
nuclei. 
Type I I : reduced binding capacity with normal binding af-
finity to soluble cell extract and nuclei (reduced number of 
receptors). 
Type III: reduced binding affinity with normal binding capac-
ity (normal number of receptors). 
Type IV: normal binding affinity and capacity to soluble cell 
extract and no nuclear uptake. 
Type V: near-normal binding affinity and capacity to soluble 
cell extract and abnormal elution of hormone-receptor complex 
from heterologous DNA-cellulose. 
Type VI was not described but would include patients with 
posttranscription defects who should show normal binding and 
nuclear uptake of 1,25-dihydroxyvitamin D3 and normal elution 
of hormone-receptor complex from heterologous DNA-cel-
lulose. Patients with types III and IV disease respond to large 
doses of 1,25-dihydroxyvitamin D3, whereas patients with types 
I , I I , and V disease respond poorly or not at all. 
Based on these findings and assuming that receptor defects 
are qualitative (and result from point mutations) and not quan-
titative (and do not result from lack of expression), it can be pre-
dicted that the stmcture of the 1,25-dihydroxyvitamin D-bind-
ing domain of the receptor is abnormal in patients with type I 
disease and that stmcture of the DNA binding domain is abnor-
mal in patients with type V disease. It is now known that two 
separate mutations exist in type V disease. Point mutations have 
been identified in each of the two "zinc fingers" which account 
for the lack of response to 1,25-dihydroxyvitamin D3 in vivo and 
abnormal nuclear uptake of the 1,25-dihydroxyvitamin D3-re-
ceptor complex in vitro in two different families with vitamin D-
dependent rickets, type II (Pike JW, personal communication). 
These results emphasize the importance of the stmcture of the 
cysteine-containing loops or "zinc fingers" in binding of 
the 1,25-dihydroxyvitamin D3-receptor complex for biologic 
function ofthe vitamin. Studies are in progress in Dr. Pike's lab-
oratory to determine whether abnormal structure of the 
1,25-dihydroxyvitamin D-binding domain of the receptor or 
abnormalities in posttranscription events are responsible for ex-
pression of the disease in other patients. He proposes to transfect 
cells that have an abnormal receptor with the gene for the normal 
vitamin D receptor to determine whether a defective receptor 
fully accounts for the disease in a given patient. 
The Role of Phosphorus in Modulating Vitamin D 
Metabolism in Health and Disease 
Previous studies in rats showed the importance of dietary 
phosphate in regulating the production of 1,25-dihydroxy-
vitamin D (3). Thus, phosphate intake varied directly with renal 
production ofthe metabolite. Also, previous studies demon-
strated the importance of restriction of phosphate intake in pre-
venting secondary hyperparathyroidism in chronic renal failure 
(4). Morris et al (5) showed that changes in phosphate intake reg-
ulate the renal production of 1,25-dihydroxyvitamin D and 
semm 1,25-dihydroxyvitamin D in nonnal subjects. They also 
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showed that phosphate restriction prevents inhibition of the renal 
synthesis of 1,25-dihydroxyvitamin D and secondary hyper-
parathyroidism even in patients with modest reductions in 
glomemlar filtration rate. Their studies indicate, therefore, that 
dietary intake of phosphorus should be limited early in the 
course of renal disease to prevent the development of secondary 
hyperparathyroidism and its sequelae. 
Clinical Disorders of Phosphorus and 
Vitamin D Metabolism 
Nesbitt et al (6) presented evidence that the renal tubular reab-
sorption of phosphate and renal synthesis of 1,25-dihydroxy-
vitamin D are closely linked. Thus, TmP/GFR or tubular phos-
phate reabsorption and plasma 1,25-dihydroxyvitamin D varied 
directiy with each other in patients with X-linked hypo-
phosphatemic rickets, tumor-induced osteomalacia, and tu-
moral calcinosis. However, there was poor correlation between 
TmP/GFR and plasma 1,25-dihydroxyvitamin D in patients 
with hereditary hypophosphatemic rickets and hypercalciuria. 
In this disorder, circulating 1,25-dihydroxyvitamin D was in-
creased and responsible for the hypercalciuria. They suggested 
that the proximal renal tubular site at which phosphate is reab-
sorbed may be important in the regulation of renal synthesis of 
1,25-dihydroxyvitamin D and that the interrelation of these two 
processes, which appear to be linked, is complex. 
Abnormal Vitamin D and Calcium Metabolism 
in Sarcoidosis and Related Diseases 
Hypercalcemia caused by increased circulating 1,25-di-
hydroxyvitamin D is a potentially preventable cause of renal 
failure and death in patients with sarcoidosis. Liel and col-
leagues (7) developed a means to identify patients who may be at 
risk to develop hypercalcemia. Their method is based on the fact 
that feedback regulation of circulating 1,25-dihydroxyvitamin D 
normally occurs in response to increases in dietary calcium. 
They found in a small number of patients with sarcoidosis and 
active disease, in contrast to normal subjects in whom serum 
1,25-dihydroxyvitamin D declined in response to increases in 
dietary calcium, that serum 1,25-dihydroxyvitamin D did not 
change. These results were interpreted to mean that since the 
production of 1,25-dihydroxyvitamin D is not normally regu-
lated, it must be synthesized at extrarenal sites in patients with 
active disease. Thus, patients with active disease may be at risk 
for developing hypercalcemia. In fact, one of the patients devel-
oped hypercalcemia in the course of a summer. 
The Effects of Race and Body Habitus on 
the Vitamin D Endocrine System 
Blacks and obese subjects have a greater bone mass than 
whites and nonobese individuals and are at less risk for develop-
ing osteoporosis and fractures of the hip (8). Blacks and obese 
whites also show decreases in semm 25-hydroxyvitamin D and 
urinary calcium and increases in semm 1,25-dihydroxyvitamin 
D and urinary cyclic adenosine 3',5'-monopho.sphate as com-
pared to nonobese white men and women. It remains unclear 
whether the altered vitamin D endocrine system in these sub-
jects is related to the increased bone mass. 
References 
1. Haussler MR. 1,25-Dihydroxyvitamin D, receptor structure and function. 
In: Kleerekoper M, Krane SM, eds. Clinical disorders of bone and mineral me-
tabolism. New York: Mary Ann Liebert, Inc, 1989 (in press). 
2. Liberman UA, Marx SJ. Hereditary resistance to 1,25-dihydroxyvitamin 
D: Pathophysiology, diagnosis, and treatment. In: Kleerekoper M, Krane SM, 
eds. Clinical disorders of bone and mineral metabolism. New York: Mary Ann 
Liebert, lnc, 1989 (in press). 
3. Tanaka Y, DeLuca HF. The control of 25-hydroxyvitamin D metabolism 
by inorganic phosphorus. Arch Biochem Biophys 1973:154:566-74. 
4. Slatopolsky E, Caglar S, Pennell JP, et al. On the pathogenesis of hyper-
parathyroidism in chronic experimental renal insufficiency in the dog. J Clin In-
vest 1971;50:492-9. 
5. Morris RC Jr, Halloran BP, Portale AA. The role of phosphorus in modu-
lating vitamin D metabolism in health and disease. In: Kleerekoper M. Krane 
SM. eds. Clinical disorders of bone and mineral metabolism. New York: Mary 
Ann Liebert, Inc, 1989 (in press). 
6. Nesbitt T, Davidai GA, Brazy PC, Drezner MK. Clinical disorders of 
phosphorus and vitamin D metabolism. In: Kleerekoper M. Krane SM. eds. 
Clinical disorders of bone and mineral metabolism. New York: Mary Ann 
Liebert, Inc, 1989 (in press). 
7. Liel Y. Basile J, Bell NH. Abnormal vitamin D and calcium metabolism in 
sarcoidosis and related diseases. In: Kleerekoper M, Krane SM, eds. Clinical 
disorders of bone and mineral metabolism. New York: Mary Ann Liebert, Inc, 
1989 (in press). 
8. Epstein S, Bell NH. The effects of race and body habitus on the vitamin D 
endocrine system. In: Kleerekoper M, Krane SM, eds. Clinical disorders 
of bone and mineral metabolism. New York: Mary Ann Liebert, Inc, 1989 
(in press). 
Henry Ford Hosp Med J—Vol 36. No 3. 1988 Vitamin D Metabolism—Bell 165 
